Alemtuzumab (Campath)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Anti-CD52 antibody that is believed to cause antibody-dependent cell-mediated cytotoxicity of cells that express the CD52 antigen on their surface: B and T lymphocytes, most monocytes, macrophages, natural killer (NK) cells, and a subpopulation of granulocytes.[1][2][3]
Route: IV
Extravasation: neutral

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Toxicity management

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2001-07-06: Initial authorization for the treatment of patients with B-cell chronic lymphocytic leukaemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate.
  • 2012-08-08: Authorization withdrawn at the request of the manufacturer, for commercial reasons

History of changes in PMDA indication

  • 2014-09-26: Initial approval for the treatment of relapsed or refractory chronic lymphocytic leukemia.
  • 2020-12-25: New indication and a new dosage for a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation.

Also known as

  • Code name: LDP-03
  • Brand names: Campath, Campath-1H, Lemtrada, MabCampath